Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diabetic retinopathy
Biotech
Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect
The buyout, which includes $2.15 billion in milestones, will give Bayer control of an eye disease implant that improved outcomes in phase 2 trials.
Nick Paul Taylor
May 6, 2026 7:20am
Boehringer inks another eye disease deal, this time with Palatin
Aug 18, 2025 10:30am
Valo abandons ROCK inhibitor after diabetic retinopathy fail
Jan 2, 2025 9:43am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Roche drops oral eye disease drug after completing phase 2
Oct 19, 2023 5:50am
Ocuphire's diabetic eye drug misses phase 2 primary endpoint
Jan 26, 2023 8:32am
